ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery

American Journal of Health-System Pharmacy

Volumn 56, Issue 8, 1999, Pages 729-764

  Andria, M L ^a   Arens, J F ^a   Baker D K , Jr ^a   Bolinger, A M ^a   Briones, G R ^a   Chen, J J ^a   Chin, A ^a   Coursin, D B ^a   Diener, K M ^a   Dranitsaris, G ^a   Farrington, J ^a   Frazier, J L ^a   Gandara, D R ^a   Goldspiel, B R ^a   Golembiewski, J A ^a   Grunberg, S M ^a   Henry, D W ^a   Hutson, P R ^a   McCauley, D L ^a   McKenna, E F ^a   Perez, E A ^a   Philip, B K ^a   Shirk, M B ^a   Slimowitz, R ^a   Solimando D A , Jr ^a   Springman, S R ^a   Stump, L S ^a   Taylor, T ^a   Wagner, B K ^a   Walton, S M ^a   more..

^a NONE

Author keywords

American Society of Health System Pharmacists; Antiemetics; Antihistamines; Antineoplastic agents; Benzamides; Benzodiazepines; Butyrophenones; Cannabinoids; Economics; Nause a; Pediatrics; Phenothiazines; Protocols; Radiation; Serotonin antagonists; Steroids, cortico ; Surgery; Toxicity; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BELLADONNA ALKALOID; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CHLORPROMAZINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; DRONABINOL; DROPERIDOL; GRANISETRON; HALOPERIDOL; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN AGONIST; THIETHYLPERAZINE; UNINDEXED DRUG;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION INJURY; RISK FACTOR; VOMITING;

EID: 0033561077     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.8.729     Document Type: Article

References (423)

1. Mitchelson F. Pharmacological agents affecting emesis: a review (part I). Drugs. 1992; 43:295-315.
2. Mitchelson F. Pharmacological agents affecting emesis: a review (part II). Drugs. 1992; 43:443-63.
3. Hanson JS, McCallum RW. The diagnosis and management of nausea and vomiting: a review. Am J Gastroenterol. 1985; 80:210-8.
4. Kris MG, Cubedden LX, Gralla RJ et al. Are more antiemetic trials with placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996; 78:2193-8.
5. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology. 1992; 77:162-84.
6. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993; 329:1790-6.
7. Naylor RJ, Inall FC. The physiology and pharmacology of postoperative nausea and vomiting. Anaesthesia. 1994; 49:2-5.
8. Chaillet MP, Cosset JM, Socie G et al. Prospective study of the clinical symptoms of therapeutic whole body irradiation. Health Phys. 1993; 64:370-4.
9. Danjoux CE, Rider WD, Fitzpatrick PJ. The acute radiation syndrome. Clin Radiol. 1979; 30:581-4.
10. DuBois A, Walker RI. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome. Gastroenterology. 1988; 95:500-7.
11. Westbrook C, Glaholm J, Barrett A. Vomiting associated with whole body irradiation. Clin Radiol. 1987; 38:263-6.
12. Henriksson R, Lomberg H, Israelsson G et al. The effect of ondansetron on radiation-induced emesis and diarrhoea. Acta Oncologica. 1992; 31:767-9.
13. Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep. 1986; 70:555-63.
14. Morrow GR. The assessment of nausea and vomiting: past problems, current issues, and suggestions for further research. Cancer. 1984; 53(suppl):2267-80.
15. Gralla RJ, Clark RA, Kris MG et al. Methodology in antivemetic trials. Eur J Cancer. 1991; 27(suppl 1):S5-8.
16. Aapro M. Methodological issues in antiemetic studies. Invest New Drugs. 1993; 11:243-53.
17. Newman V, Fullerton JT, Anderson PO. Clinical advances in the management of severe nausea and vomiting during pregnancy. J Obstet Gynecol Neonatal Nurs. 1993; 22:483-90.
18. Palazzo MGA, Strunin L. Anaesthesia and emesis: I. Etiology. Can Anaesth Soc J. 1984; 31:178-87.
19. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laslo J, ed. Antiemetics and cancer chemotherapy. Baltimore: Williams & Wilkins; 1982:1-5.
20. Coates A, Abraham S, Kaye SB et al. On the receiving endpatient perception of the side effects of cancer chemotherapy. Br J Cancer Clin Oncol. 1983; 19:203-8.
21. Laszlo J, Gralla RJ, Einhorn LH et al. Antiemetics: a round table discussion. Drugs. 1983; 25(suppl 1):74-80.
22. Graves T. Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment. Pharmacotherapy. 1992; 12:337-45.
23. Coates A, Gebaki V, Signorine D et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol. 1992; 10:1833-8.
24. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992; 1:331-40.
25. O'Brien BJ, Rusthoven J, Rocchi A et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and costs: survey of five Canadian centres. Can Med Assoc J. 1993; 149:296-302.
26. Osoba D, Zee B, Warr D et al. Quality of life studies in chemotherapy-induced emesis. Oncology. 1996; 53(suppl 1):92-5.
27. Redd WH, Andrykowski MA. Behavioral interventions in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982; 50:1018-29.
28. Cotanch PH. Relaxation training for control of nausea and vomiting in patients receiving chemotherapy. Cancer Nurs. 1983; 6:277-83.
29. Stoudemire A, Cotanch P, Laszlo J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. Arch Intern Med. 1984; 144:1029-33.
30. Wickham R. Managing chemotherapy-related nausea and vomiting: the state of the art. Oncol Nurs Forum. 1989; 16:563-74.
31. Burish TG, Jenkins RA. Effectiveness of blofeedback and relaxation training in reducing the side effects of cancer chemotherapy. Cancer Nurs. 1983; 6:277-83.
32. King CR. Nonpharmacologic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum. 1997; 24:41-8.
33. Bigos S, Bowyer O, Braen G et al. Acute low back problems in adults. Clinical practice guideline no.14. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, December 1994; AHCPR publication no. 95-0642.
34. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nurs Res. 1989; 38:286-8.
35. Rhodes VA, Johnson MH, McDaniel RW. Nausea, vomiting, and retching: the management of the symptom experience. Semin Oncol Nurs. 1995; 11:256-65.
36. Blower P. A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol. 1995; 22(suppl 10):3-5.
37. Costall B, Domeney AM, Naylor J et al. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology. 1986; 25:959-61.
38. Matsuoka O, Tsuchiya T, Furukawa Y. The effect of x-irradiation on 5-hydroxytryptamine (serotonin) contents in the small intestines of experimental animals. J Radiat Res. 1962; 32:104-8.
39. Gralla RJ, Itri LM, Pisko CE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981; 305:905-9.
40. Homesley HD, Gainey JM, Jobson VW et al. Cisplatin chemotherapy and emesis in patients given metoclopramide and controls. N Engl J Med. 1982; 307:250. Letter.
41. Cubeddu LX, Hoffmann IS, Fuenmayor NT et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990; 322:810-6.
42. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer. 1990; 26(suppl 1):S23-7.
43. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3:1379-84.
44. DeMulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind cross-over study. Ann Intern Med. 1990; 113:834-40.
45. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Eur J Cancer Clin Oncol. 1989; 25(suppl 1):535-9.
46. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet. 1991; 338:483-7.
47. Matty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990; 322:816-21.
48. Wilder-Smith OHG, Borgeat A, Chappuis P et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer. 1993; 72:2239-41.
49. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989; 7:108-14.
50. Gandara DR. Progress in control of acute and delayed emesis induced by cisplatin. Eur J Cancer. 1991; 27:9-11.
51. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med. 1982; 307:1476-80.
52. Morrow GR, Rosenthal SN. Models, mechanisms and management of anticipatory nausea and vomiting. Oncology. 1996; 53:4-7.
53. Tyc VL, Mulhern RK. Anticipatory nausea and vomiting in pediatric cancer patients: an analysis of conditioning and coping variables. Dev Behav Pediatr. 1997; 18:27-33.
54. Laszlo J, Clark RA, Hanson DC et al. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnestic, and anxiolytic effects. J Clin Oncol. 1985; 3:864-9.
55. Triozzi PL, Goldstein D, Laszlo J. Contributions of hemzodiazepines to cancer therapy. Cancer Invest. 1988; 6:103-11.
56. Malik IA, Khan WA, Qazilbash M et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea, and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995; 18(2):170-5. Abstract.
57. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15:103-9.
58. Jordan NS, Schauer PK, Schauer A et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol. 1985; 3:559-61.
59. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983; 25(suppl 1):1-7.
60. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol. 1984; 2:1170-6.
61. Nerenz DR, Leventhal H, Easterling DV et al. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J Clin Oncol. 1986; 4:224-33.
62. Triozzi PL, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs. 1987; 34:136-49.
63. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs. 1983; 25(suppl 1):8-17.
64. Tortorice PV, O'Connell MB. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy. 1990; 10:129-45.
65. Hesketh PJ, Beck T, Uhlenhopp M et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995; 13:2117-22.
66. Bilgrami S, Fallon BG. Chemotherapy-induced nausea and vomiting: easing patients' fear and discomfort with effective antiemetic regimens. Postgrad Med. 1993; 94:55-64.
67. 3 receptor antagonists. Support Care Cancer 1994; 2:286-92.
68. Hrushesky WJM. The clinical application of chronobiology to oncology. Am J Anat. 1983; 168:519-42.
69. Bremer K, for the Granisetron Study Group. A single blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5 day cytostatic therapy. Eur J Cancer. 1992; 28A: 1018-22.
70. Carden PA, Mitchell SL, Water KD et al. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. J Clin Oncol. 1990; 8:1531-5.
71. Chevallier B, on behalf of the Granisetron Study Group. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose clsplatin in a single-blind study. Eur J Cancer. 1990; 26:533-6.
72. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer. 1990; 26(suppl 1):S28-32.
73. Marty M, D'Allens H. Etude randomisee en double-insu comparant l'efficacite de l'ondansetron selon deux modes d'administration: injection unique et perfusion continue. Cahiers Cancer. 1990; 2:541-6.
74. Marty M, on behalf of the Granisetron Study Group. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer. 1992; 28A (suppl):S12-6.
75. 3 antagonist ondansetron - an effective outpatient anti-emetic in cancer treatment. Arch Dis Child. 1990; 65:822-5.
76. Soukop M, on behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer. 1990; 26:515-29.
77. Dicato MA. Oral treatment with ondansetron in the outpatient setting. Eur J Cancer. 1991; 27(suppl 1):S18-9.
78. Fraschini G, Ciociola A, Esparza L et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991; 9:1268-74.
79. Hainsworth J, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991; 9:721-8.
80. Lemerle J, Amaral D, Southall DP et al. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer. 1991; 27:1081-3.
81. Rosso R, Campora E, Cetto G et al. Oral ondansetron (GR 38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res. 1991; 11:937-40.
82. Blijham GH, on behalf of the Granisetron Study Group. Does granisetron remain effective over multiple cycles? Eur J Cancer. 1992; 28A:S17-21.
83. Diehl V, on behalf of the Granisetron Study Group. Fractionated chemotherapy - granisetron or conventional antiemetics? Eur J Cancer. 1992; 28A:S21-8.
84. Kamanabrou D, on behalf of the Granisetron Study Group. Intravenous granisetron - establishing the optimal dose. Eur J Cancer.1992; 28A:S6-11.
85. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993; 118:407-13.
86. Buser KS, Joss RA, Piquet D et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol. 1993; 4:475-9.
87. De Wet M, Falkson G, Rapoport BL. Repeated use of granisetron in patients receiving cytostatic agents. Cancer. 1993; 71:4043-9.
88. Ohmatsu H, Eguchi K, Shinkai T et al. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res. 1994; 85:1151-8.
89. Hachimi-Idrissi S, De Schepper J, Maurus R et al. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy. Eur J Cancer. 1993; 29A:854-6.
90. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer. 1993; 29A:1669-72.
91. 3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol. 1993; 4:481-4.
92. 3 receptors, in the treatment of antineo-plastic drug-induced nausea and vomiting in children. J Med. 1993; 24:161-70.
93. Warr D, Wilan A, Venner P et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer. 1993; 29A:33-6.
94. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. Am J Clin Oncol. 1994; 17:137-46.
95. Jacobson SJ, Shore RW, Greenberg M et al. The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol Oncol. 1994; 16:231-5.
96. Miyajima Y, Numata S, Katayama I et al. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol. 1994; 16:236-41.
97. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5 hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994; 12:2204-10.
98. Alvarez O, Freeman A, Bedros A et al. Randomized double-blind crossover of ondansetron-dexamethasone versus on-dansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. Am J Pediatr Hematol Oncol. 1995; 17:145-50.
99. Clavel M, Bonneterre J, d'Allens H et al. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer. 1995; 31A:15-9.
100. Craft AW, Price L, Eden OB et al. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol. 1995; 25:28-32.
101. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child. 1995; 73:243-5.
102. Mahlen K, Quintana E, Pinkerton CR et al. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr. 1995; 126:309-13.
103. Holdsworth MT, Raisch DW, Duncan MH et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother. 1995; 29:16-21.
104. Leclerc JM, Greenberg M, Lau R et al. Open label IV dolasetron mesylate in pediatric patients receiving moderately to highly emetogenic chemotherapy: pharmacokinetics, efficacy and safety. Support Care Cancer. 1995; 3:343. Abstract.
105. Navari RM, Madajewicz S, Anderson N et al. Oral on-dansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995; 13:2408-16.
106. Yanofsky R, Pyesmany A, Pritchard S et al. Open label oral dolasetron mesylate in pediatric patients receiving moderately to highly emetogenic chemotherapy: pharmacokinetics, efficacy and safety. Support Care Cancer. 1995; 3:344. Abstract.
107. Fauser A, Duclos B, Chemaissani A et al. Therapeutic equivalence of single oral doses of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer. 1996; 32A: 1523-9.
108. Kris MG, Pendergrass KB, Navari TH et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997; 15:2135-8.
109. Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol. 1993; 119:555-9.
110. Anzamet product information. Kansas City, MO: Hoechst Marion Roussel; 1997.
111. Benedict CR, Arbogast R, Martin L et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteer. J Cardiovasc Pharmacol. 1996; 28:53-9.
112. Sledge GW, Einhorm L, Nagy C. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992; 70:2524-8.
113. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992; 49:295-304.
114. Roila F. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology. 1993; 50:163-7.
115. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol. 1994; 5:579-84.
116. Chiou TJ, Wei CH, Hsieh et al. Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis. Chung Hua I Hsueh Tsa Chih. 1995; 56:23-30.
117. Tsavaris N, Charalambidis G, Ganas N et al. Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to electrolyte imbalance. Acta Oncol. 1995; 34:243-6.
118. Soukop M. Management of cyclophosphamide-induced emesis over repeat courses. Oncology. 1996; 53:39-45.
119. Chevallier B, Cappelaere P, Splinter T et al. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer. 1997; 5:22-30.
120. Du Bois A, McKenna CJ, Andersson H et al. A randomized, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis by carboplatin chemotherapy. Oncology. 1997; 54:7-14.
121. Italian Group for Antiemetic Research. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in prevention of cisplatin-induced emesis. Lancet. 1992; 340:96-9.
122. Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol. 1993; 11:2396-404.
123. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990; 8:1063-9.
124. Kaasa S, Kvaloy S, Dicato MA et al. A comparison of on-dansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer. 1990; 26:311-4.
125. Marschner NW, Adler M, Nagel GA et al. Double-blind, randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer. 1991; 27:1137-40.
126. Noble A, Bremer K, Goedhals L et al. A double-blind, randomised crossover comparison of granisetron and on-dansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference. Eur J Cancer. 1994; 30A: 1083-8.
127. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis; a multicenter double-blind, randomized, parallel-group study. Oncology. 1994; 51:113-8.
128. Bonneterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy: a cross-over study. Bull Cancer. 1995; 82:1038-43.
129. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol. 1995; 6:805-10.
130. Stewart A, McQuade B, Cronje JDE et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide induced emesis in out-patients: a multicentre double-blind, double-dummy, randomised, parallel group study. Oncology. 1995; 52:202-10.
131. Harris E, Hakimian D, Dempsey C et al. Comparative outcomes of granisetron and ondansetron for prevention of chemotherapy induced nausea and vomiting. Proc Am Soc Clin Oncol. 1997; 15:540. Abstract.
132. Martoni A, Angelelli B, Guaraldi M et al. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer. 1996; 32:82-5.
133. Mantovani G, Maccio A, Curieli L et al. Comparison of granisetron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 1996; 77:941-8.
134. Pion JM, Fournier C, Darloy et al. Oral granisetron vs on-dansetron. A comparative double-blind cross-over multi-center study of preventive anti-emetic in moderately emetogenic chemotherapy by the French Northern Oncology group. Proc Am Soc Clin Oncol. 1997; 15:530. Abstract.
135. Perez EA, Hesketh P, Sanbach J et al. Comparison of single-dose oral granisetron versus intravenous ondanseron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998; 16:754-60.
136. Roila F for the Italian Group for Antiemetic Research. On-dansetron versus granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis. Ann Oncol. 1995; 6:805-10.
137. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996; 32A:807-13
138. Hesketh P, Navari R, Grote T et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 1996; 14:2242-9.
139. Lofters W, Pater J, Zee et al. Phase III double-blind comparison of dolasetron mesylate and ondanseton: an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997; 15:2966-73.
140. Parley PA, Dempsey CL, Shillington AA et al. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm. 1997; 54:2478-82.
141. Marr HE, Davey PT, Boyle EA et al. Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology. 1994; 48:283-92.
142. Gralla RJ, Navari RM, Hesketh PJ et al. Single dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998; 16:1568-73.
143. Navari RM, Pendergrass KB, Grote TH et al. All oral regimens of dolasetron and dexamethasone to prevent emesis caused by high dose cisplatin. Proceedings of American Society of Clinical Oncology, Philadelphia, PA, May 20. 1996; 15:537.
144. Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer. 1992; 66:192-7.
145. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992; 10:1969-75.
146. Pectasides D, Mylonakis A, Varthalitis J et al. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis. Oncology. 1997; 54:1-6.
147. Krzakowski M, Graham E, Goedhal L et al. A multicenter, double-blind comparison of IV and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. Anticancer Drugs. 1998; 9:593-8.
148. Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer. 1994; 69:967-71.
149. Perez EA, Navari RM, Kaplan HG et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997; 5:31-7.
150. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol. 1994; 17:97-102.
151. Kris MG, Grunberg SM, Gralla RJ et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol. 1994; 12:1045-9.
152. Harman GS, Omura GA, Ryan K et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol. 1996; 38:323-8.
153. Pendergrass K, Audhuy B, Hesketh P et al. Analysis of optimal dose from eight pooled clinical trials assessing the acute antiemetic efficacy of iv dolasetron mesylate after emetogenic chemotherapy. Proc Am Soc Clin Oncol. 1996; 15:547. Abstract.
154. Rubenstein E, Fauser A, Grote J et al. Determination of optimal dolasetron mesylate dose in prevention of acute nausea and vomiting after moderately emetogenic chemotherapy using pooled data from three pivotal trials. Proc Am Soc Clin Oncol. 1996; 15:532. Abstract.
155. Thant M, Pendergrass K, Harman G et al. Double-blind, randomized study of the dose-response relationship across five single doses of iv dolasetron mesylate for prevention of acute nausea and vomiting after cisplatin chemotherapy. Proc Am Soc Clin Oncol. 1996; 15:533. Abstract.
156. Yeilding A, Bertoli L, Eisenberg P et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol. 1996; 19:619-23.
157. Grote TH, Pineda LF, Figlin RA et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinumcontaining chemotherapy. Cancer J Sci Am. 1997; 3:45-51.
158. Rubenstein EB, Gralla RJ, Hainsworth JD et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer. 1997; 79:1216-24.
159. Roila F, Tonato M, Cognetti F et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991; 9:675-8.
160. Smith DB, Newlands ES, Rustin GJS et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemother-apy. Lancet. 1991; 338:487-90.
161. Smyth JF, Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J. 1991; 303:1423-6.
162. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995; 332:1-5.
163. Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol. 1995; 13:2417-26.
164. Latreille J, Stewart D, Laberge F et al. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high-dose cisplatin chemotherapy. Support Care Cancer. 1995; 3:307-12.
165. Nukariya N, Nakarai I, Kobayaski H et al. A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis. Gan To Kagaku Ryoho. 1995; 22:1821-9.
166. Tsukuda M, Kohno H, Enomoto H et al. Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin. Gan To Kagaku Ryoho. 1995; 22:1377-82.
167. Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron, and on-dansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol. 1996; 7:945-52.
168. Ozono S, Okajima E, Hirao YK et al. A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis-outcomes of a multicenter randomized comparative study using the Central Registration Method. Can To Kagaku Ryoho. 1997; 24:349-56.
169. Joss RA, Bacchi M, Buser K et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Ann Oncol. 1994; 5:253-8.
170. Proleukin package insert. Emeryville, CA: Chiron Corp; 1994.
171. Smith KA. T cell growth factor and glucocorticoids: opposing regulatory hormones in neoplastic T-cell growth. Immunobiology. 1982; 161:157-73.
172. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol. 1984; 133:273-6.
173. Schleimer RP, Jacques A, Shin HS et al. Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. J Immunol. 1984; 132:266-71.
174. Roman AD, Gandara DR, Ferez EA et al. Evaluation of an oral three drug regimen in the control of acute and delayed emesis after cisplatin. Proc Am Soc Clin Oncol. 1998; 23:68a.
175. Cassileth PA, Lusk EJ, Torri S et al. Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia. Ann Intern Med. 1984; 100;701-2.
176. Zaglama NE, Rosenblum SL, Sartiano GP et al. Single high-dose intravenous dexamethasone as an anti-emetic in cancer chemotherapy. Oncology. 1986; 43:27-32.
177. Chiara S, Campora E, Lionetto R et al. Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol. 1987; 10:264-7.
178. Markman M, Sheidler V, Ettinger DS et al. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984; 311:549-52.
179. Goldstein D, Levi JA, Woods RL. Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Oncology. 1989; 46:105-8.
180. Moertel CG, Reitemeier RJ, Gage RP et al. A controlled clinical evaluation of antiemetic drugs. JAMA. 1963; 186:116-8.
181. Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology. 1992; 49:279-85.
182. Sullivan MJ, Abbott GD, Robinson BA. Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. N Z Med J. 1992; 105:369-71.
183. Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer chemotherapy induced nausea and vomiting in children. Clin Oncol. 1993; 5:11-4.
184. Kolecki P, Wachowiak J, Beshari SE. Ondansetron as an effective drug in prophylaxis of chemotherapy-induced emesis in children. Actas Haematol Pol. 1993; 24:115-22.
185. Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm. 1996; 53:294-304.
186. Quercia RA, Zhang J, Fan C et al. Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 1997; 54:1404-6.
187. Mehta P, Gross S, Graham-Pole J et al. Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children. J Pediatr. 1986; 108:774-6.
188. Graham-Pole J, Weare J, Engel S et al. Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol. 1986; 4:1110-3.
189. Van Hoff J, Olszewski D. Lorazepam for the control of chemotherapy-related nausea and vomiting in children. J Pediatr. 1988; 113:146-9.
190. Marshall G, Kerr S, Vowels M et al. Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. J Pediatr. 1989; 115:156-60.
191. Relling MV, Mulhern RK, Fairclough D et al. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr. 1993; 123:811-6.
192. Buxton MJ, O'Brien BJ. Economic evaluation of on-dansetron, preliminary analysis using clinical trial data prior to price setting. Br J Cancer. 1992; 66(suppl 19):S64-7.
193. Johnson NE, Nash DB, Carpenter CE et al. Ondansetron: costs and resource utilization in a U.S. teaching hospital setting. Pharmacoeconomics. 1993; 3:471-81.
194. Tanneberger S, Lelli G, Martoni A et al. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost benefit index). J Chemother. 1992; 4:326-31.
195. Cox F, Hirsch J. Ondansetron: a cost-effective advance in antiemetic therapy. Oncology. 1993; 50:186-90.
196. Cunningham D, Gore M, Davidson N et al. The real costs of emesis - an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer. 1993; 29A:303-6.
197. Zammit-Lucia J. Modeling budgetary impact from decision makers. Anticancer Drugs. 1993; 4(suppl 3):21-5.
198. Bleiberg HH, Spielmann M, Falkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther. 1995; 17:38-51.
199. Johnson N, Bosanquet N. Cost effectiveness of 5-hydroxy-tryptamine-3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer Drugs. 1995; 6:243-9.
200. Dranitsaris G, De Angelis C, Warr D et al. Pharmacoeconomic analysis of prophylactic treatments for emesis secondary to breast cancer chemotherapy. Can J Hosp Pharm. 1995; 48:266-75.
201. Zbrozek AS, Cantor SB, Cardenas MP et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm. 1994; 51:1555-63.
202. Casteels-Van Daele M, Jaeken J, Van Der Schueren P et al. Dystonic reactions in children caused by metoclopramide. Arch Dis Child. 1970; 45:130-3.
203. Cousin J, Katende G, Pauli A et al. L'intoxication par metoclopramide chez l'enfant. J Sci Med Lille. 1973; 91:1.
204. Low LC, Goel KM. Metoclopramide poisoning in children. Arch Dis Child. 1980; 55:310-1.
205. Bateman DN, Craft AW, Nicholson E et al. Dystonic reactions and the pharmacokinetics of metoclopramide in children. Br J Clin Pharmacol. 1983; 15:557-9.
206. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr. 1984; 104:138-40.
207. Allen JC, Gralla R, Reilly L et al. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol. 1985; 3:1136-41.
208. Howrie DL, Felix C, Wollman M et al. Metoclopramide as an antiemetic agent in pediatric oncology patients. Drug Intell Clin Pharm. 1986; 20:122-4.
209. Campora E, Vidili G, Oliva C et al. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR 38032F). Oncology. 1991; 48:403-5.
210. 3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin Oncol. 1991; 3:199-203.
211. Du Bois A, Meerpohl HG, Vach W et al. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992; 28:450-7.
212. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinoid and marijuana. Ann Intern Med. 1997; 126:791-8.
213. Navari RM, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced eraesis. J Clin Oncol. 1995; 13:1242-8.
214. The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Onc. 1997; 15:124-30.
215. Strum D, McDermed J, Abrahono-Umcli R et al. Management of cisplatin-induced delayed onset nausea and vomiting: preliminary results and 2 drug regimens. Proc Am Soc Clin Oncol. 1985; 4:263. Abstract.
216. Clark RA, Kris MG, Tyson LB et al. Antiemetic trials to control delayed vomiting following high-dose cisplatin. Proc Am Soc Clin Oncol 1986; 5:257. Abstract.
217. Sridhar KS, Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer. 1988; 61:1508-17.
218. Scarantino CW, Ornitz RD, Hoffman LG et al. On the mechanism of radiation-induced emesis: the role of serotonin. Int J Radiat Oncol Biol Phys. 1994; 30:825-30.
219. Roberts JT, Priestman JT. A review of ondansetron in the management of radiotherapy-induced emesis. 1993; 50:173-9.
220. Coia LR, Moylan DJ. Introduction to clinical radiation oncology. Madison, WI: Medical Physics Publishing; 1991.
221. Tyers MB, Bunce KT, Humphrey PP. Pharmacological and ati-emetic properties of ondansetron. Eur J Cancer Clin Oncol. 1989; 25(suppl 1):S515-9.
222. Lucraft HH, Palmer MK. Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol. 1982; 33:621-2.
223. Priestman TJ, Priestman SG. An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol. 1984; 35:265-6.
224. Priestman TJ. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol. 1989; 25(suppl 1):S29-33.
225. Priestman TJ, Roberts JT, Lucraft H et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol. 1990; 2:71-5.
226. Collis CH, Priestman TJ, Priestman S et al. The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol. 1991; 3:241-3.
227. Franzen L, Nyman I, Hagberg H et al. A randomized placebo-controlled study with ondansetron in patients undergoing fractionated chemotherapy. Am Aniol 1996; 7:587-92.
228. 3 antagonist. Bone Marrow Transplant 1991; 7:431-3.
229. 3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant. 1991; 7:439-41.
230. Logue JP, Magee B, Hunter RD et al. The antiemetic effect of granisetron in lower hemibody radiotherapy. Clin Oncol. 1991; 247-9.
231. Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology. 1992; 49:279-85.
232. Rosenthal SA, Marquez CM, Hourigan HP et al. Ondansetron for patients given abdominal radiotherapy. Lancet. 1992; 339:490.
233. Sullivan MJ, Abbott GD, Robinson BA. Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. N Z Med J. 1992; 105:369-71.
234. Tiley C, Powles R, Catalano J et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma. 1992; 7:317-21.
235. Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 1993; 5:358-63.
236. Spitzer TR, Bryson JC, Cirenza E et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. Clin Oncol. 1994; 12:2432-8.
237. Prentice HG, Cunningham S, Gandhi L et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant. 1995; 15:445-8.
238. Bey P, Wilkinson P, Resbeut M et al. A double-blind, placebo-controlled trial of iv dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 1996; 4:378-83.
239. 3 antagonist. Bone Marrow Transplant. 1991; 7:431-3.
240. Lippens RJ, Broeders GC. Ondansetron in radiation therapy of brain tumor in children. Pediatr Hematol Oncol. 1996; 13:247-52.
241. Holt JAG. A trial of thiethylperazine (Torecan) in patients suffering from radiation sickness. Med J Austr. 1965; 279-81.
242. Burnette PK, Perkins J. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. Pharmacotherapy. 1992; 12:120-31.
243. Tami JA, Waite WW. Metoclopramide suppository considerations. Drug Intell Clin Pharm. 1988; 22:268-9. Letter.
244. Vance JP, Neill RS, Norris W. The incidence and aetiology of post-operative nausea and vomiting in a plastic surgical unit. Br J Plast Surg. 1973; 26:336-9.
245. King MJ, Milazkiewicz R, Carli F et al. Influence of neostigmine on postoperative vomiting. Br J Anaesth. 1988; 61:403-6.
246. Cohen MM, Cameron CB, Duncan PG. Pediatric anesthesia morbidity and mortality in the perioperative period. Anesth Analg. 1990; 70:160-7.
247. Kamath B, Curran J, Hawkey C et al. Anaesthesia, movement and emesis. Br J Anaesth. 1990; 64:728-30.
248. Parnass SM, McCarthy RJ, Ivankovich AD. The role of pain as a cause of postoperative nausea/vomiting after outpatient anesthesia. Anesth Analg. 1992; 74:5233. Abstract.
249. Lerman J. Surgical and patient factors involved in postoperative nausea and vomiting. Br J Anaesth. 1992; 69(suppl 1):24S-32S.
250. Watcha MF, Simeon RM, White PF et al. Effect of propofol on the incidence of postoperative vomiting after strabismus surgery in pediatric outpatients. Anesthesiology. 1991; 75:204-9.
251. Gan TJ, Ginsberg B, Grant AP et al. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. Anesthesiology. 1996; 85:1036-42.
252. Tramer M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth. 1997; 78:247-55.
253. Morrison JD, Clarke RSJ, Dundee JW. Studies of drugs given before anesthesia XXI: droperidol. Br J Anaesth. 1970; 42:730-5.
254. Patton CM, Moon MR, Dannemiller FJ. The prophylactic antiemetic effect of droperidol. Anesth Analg. 1974; 53:361-4.
255. Winning TJ, Brock-Utne JG, Downing JW. Nausea and vomiting after anesthesia and minor surgery. Anesth Analg. 1977; 56:674-7.
256. Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anesth Analg. 1979; 58:396-400.
257. Loeset EA, Bennett G, Stanley TH et al. Comparison of droperidol, haloperidol and prochlorperazine as postoperative anti-emetics. Can Anaesth Soc J. 1979; 26:125-7.
258. Rita L, Goodarzi M, Seleny F. Effect of low dose dropetidol on postoperative vomiting in children. Can Anaesth Soc J. 1981; 28:259-62.
259. McKenzie R, Wadhwa RK, Uy NTL et al. Antiemetic effectiveness of intramuscular hydroxyzine compared to intramuscular droperidol. Anesth Analg. 1981; 60:783-8.
260. Mortensen PT. Droperidol (Dehydrobenzperidol): post-operative anti-emetic effect when given intravenously to gynaecological patients. Acta Anaesthesiol Scand. 1982; 26:48-52.
261. Abramowitz MD, Oh TH, Epstein BS et al. The antiemetic effect of droperidol following outpatient strabismus surgery in children. Anesthesiology. 1983; 59:579-83.
262. Cohen SE, Woods WA, Wyner J. Antiemetic efficacy of droperidol and metoclopramide. Anesthesiology. 1984; 60:67-9.
263. Layfield DJ, Walker AKY. Premeditation for children with oral trimeprazine and droperidol. Anaesthesia. 1984; 39:32-4.
264. O'Donovan N, Shaw J. Nausea and vomiting in day-case dental surgery: the use of low dose droperidol. Anaesthesia. 1984; 39:1172-6.
265. Santos A, Datta S. Prophylactic use of droperidol for control of nausea and vomiting during spinal anesthesia for cesarean section. Anesth Analg. 1984; 63:85-7.
266. Korttila K, Kauste A, Tuominen M et al. Droperidol prevents and treats nausea and vomiting after enflurane anaesthesia. Eur J Anaesthesiol. 1985; 2:379-85.
267. Valanne J, Korttila K. Effect of a small dose of droperidol on nausea, vomiting and recovery after outpatient enflurane anaesthesia. Acta Anaesthesiol Scand. 1985; 29:359-62.
268. Hardy JF, Charest J, Girouard G et al. Nausea and vomiting after strabismus surgery in preschool children. Can Anaesth Soc J. 1986; 33:57-62.
269. Kauste A, Tuominen M, Heikkinen H et al. Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae. Eur J Anaesthesiol. 1986; 3:1-9.
270. Lerman J, Eustis S, Smith DR. Effect of droperidol pretreatment on postanesthetic vomiting in children undergoing strabismus surgery. Anesthesiology. 1986; 65:322-5.
271. Madej TH, Simpson KH. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery. Br J Anaesth. 1986; 58:884-7.
272. Van Den Berg AA, Lambourne A, Yazji NS et al. Vomiting after ophthalmic surgery. Effects of intra-operative antiemetics and postoperative oral fluid restriction. Anesthesia. 1987; 42:270-6.
273. Tigerstedt I, Salmela L, Aromaa U. Double-blind comparison of transdermal scopolamine, droperidol and placebo against postoperative nausea and vomiting. Acta Anaesthesiol Scand. 1988; 32:454-7.
274. Chestnut DH, Owen CL, Geiger M et al. Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section. South Med J. 1989; 82:1224-7.
275. Christensen S, Farrow-Gillespie A, Lerman J. Incidence of emesis and postanesthetic recovery after strabismus surgery in children: a comparison of droperidol and lidocaine. Anesthesiology. 1989; 70:251-4.
276. Pandit SK, Kothary SP, Pandit UA et al. Dose-response study of droperidol and metoclopramide as antiemetics for outpatient anesthesia. Anesth Analg. 1989; 68:798-802.
277. Melnick B, Sawyer R, Karambelkar D et al. Delayed side effects of droperidol after ambulatory general anesthesia. Anesth Analg. 1989; 69:748-51.
278. Jorgensen NH, Coyle JP. Intravenous droperidol decreases nausea and vomiting after alfentanil anesthesia without increasing recovery time. J Clin Anesth. 1990; 2:312-6.
279. Larsson S, Jonmarker C. Postoperative emesis after pediatric strabismus surgery: the effect of dixyrazine compared to droperidol. Acta Anaesthesiol Scand. 1990; 34:227-30.
280. Brown RE, James DJ, Weaver RG et al. Low-dose droperidol versus standard-dose droperidol for prevention of postoperative vomiting after pediatrie strabismus surgery. J Clin Anesth. 1991; 3:306-9.
281. Blanc VF, Ruest P, Milot J et al. Antiemetic prophylaxis with promethazine or droperidol in paediatric outpatient strabismus surgery. Can J Anesth. 1991; 38:54-60.
282. Alon E, Himmelseher S. Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide. Anesth Analg. 1992; 75:561-5.
283. Liu YC, Rang HM, Liou CM et al. Comparison of antiemetic effect among ephedrine, droperidol, and metoclopramide in pediatric inguinal hemioplasty. Acta Anaesthesiol Sin. 1992; 30:37-41.
284. Fujii Y, Tanaka H. Postoperative anti-emetic effects of low dose droperidol. Mosui. 1993; 42:694-7.
285. Klockgether-Radke A, Demmel C, Braun U et al. Emesis and the oculocardiac reflex. Drug prophylaxis with droperidol and atropine in children undergoing strabismus surgery. Anaesthesist. 1993; 42:356-60.
286. Lawhorn CD, Brown RE, Schmitz ML et al. Prevention of postoperative vomiting in pediatric outpatient strabismus surgery. Anesthesiology. 1993; 79:A1196. Abstract.
287. Pendeville PE, Veyckemans F, Van Boven MJ et al. Open placebo controlled comparison of the antiemetic effect of droperidol, metoclopramide, or a combination of both in pediatric strabismus surgery. Acta Anaesthesiol Belg. 1993; 44:3-10.
288. Peterson MD, Bishop J, Tanner K. Comparison of droperidol and ondansetron for prevention of vomiting after strabismus surgery in children. Anesth Analg. 1993; 76:S329. Abstract.
289. Furst SR, Rodarte A. Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. Anesthesiology. 1994; 81:799-803.
290. Heim C, Munzer T, Listyo R. Ondansetron versus droperidol: treatment of postoperative nausea and vomiting. Comparison of efficiency, side-effects and acceptance by gynaecological inpatients. Anaesthesist. 1994; 43:504-9.
291. Ummenhofer W, Frei FJ, Urwyler A et al. Effects of on-dansetron in the prevention of postoperative nausea and vomiting in children. Anesthesiology. 1994; 81:804-10.
292. Davis PJ, McGowan FX, Landsman I et al. Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery. Anesthesioiogy. 1995; 83:956-60.
293. Desilva PHDP, Darvish AH, McDonald SM et al. The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopiamide in the prevention of nausea and vomiting after major gynecologic surgery. Anesth Analg. 1995; 81:139-43.
294. Grond S, Lynch J, Diefenback C et al. Comparison of on-dansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery. Anesth Analg. 1995; 81:603-7.
295. Kymer PJ, Brown RE, Lawhorn CD et al. The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. J Clin Anesth. 1995; 7:35-9.
296. Fortney JT, Gan TJ, Graczyk S et al. A comparison of the efficacy, safety and patient satisfaction of ondansetron ver-sus droperidol as antiemetics for elective outpatient surgical procedures. Anesth Analg. 1998; 86:731-8.
297. Handley AJ. Metoclopramide in the prevention of post-operative nausea and vomiting. Br J Clin Pract. 1967; 21:460-2.
298. Dobkin AB. Perphenazine in clinical anesthesia. Can Anaesth Soc J. 1968; 15:80-91.
299. Clark MM, Storrs JA. The prevention of postoperative vomiting after abortion: metoclopramide. Br J Anaesth. 1969; 41: 890-3.
300. Ellis FR, Spence AA. Clinical trials of metoclopramide (Maxolon) as an antiemetic in anaesthesia. Anaesthesia. 1970; 25:368-71.
301. Shah ZP, Wilson J. An evaluation of metoclopramide (Maxolon) as an anti-emetic in minor gynaecological surgery. Br J Anaesth. 1972; 44:865-8.
302. Dundee JW, Clarke RSJ. The premedicant and antiemetic action of metoclopramide. Postgrad Med J. 1973; 49(suppl):34-7.
303. Assaf RAE, Clarke RSJ, Dundee JW et al. Studies of drugs given before anaesthesia XXIV: metoclopramide with morphine and pethidine. Br J Anaesth. 1974; 46:514-9.
304. Dundee JW, Clarke RSJ, Howard PJ. Studies of drugs given before anesthesia XXIII: metoclopramide. Br J Anaesth. 1974; 46:509-13.
305. Cooke RD, Comyn DJ, Ball RW. Prevention of post-operative nausea and vomiting by domperidone. A double-blind randomised study using domperidone, metoclopramide and a placebo. S Afr Med J. 1979; 56:827-9.
306. Diamond MJ, Keeri-Szanto M. Reduction of postoperative vomiting by preoperative administration of oral metoclopramide. Can Anaesth Soc J. 1980; 27:36-9.
307. Rao TL, Madhavareddy S, Chinthagada M et al. Metoclopramide and cimetidine to reduce gastric fluid pH and volume. Anesth Analg. 1984; 63:1014-6.
308. Spelina KR, Gerber HR, Pagels IL. Nausea and vomiting during spinal anesthesia. Effect of metoclopramide and domperidone: a double-blind trial. Anaesthesia. 1984; 39:132-7.
309. Waldmann CS, Verghese C, Short SM et al. The evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients. Br J Clin Pharmacol. 1985; 19:307-10.
310. Chestnut DH, Vandewalker GE, Owen CL et al. Administration of metoclopramide for prevention of nausea and vomiting during epidural anesthesia for elective cesarean section. Anesthesiology. 1987; 66:563-6.
311. Miller CD. Silent regurgitation in day case gynaecological patients. Anaesthesia. 1988; 43:321-3.
312. Williams JJ, Goldberg ME, Boerner TF et al. A comparison of three methods to reduce nausea and vomiting after alfentanil anesthesia in outpatients. Anesth Analg. 1989; 68:S311.
313. Broadman LM, Ceruzzi W, Patane PS et al. Metoclopramide reduces the incidence of vomiting following strabismus surgery in children. Anesthesiology. 1990; 72:245-8.
314. Bone ME, Wilkinson DJ, Young JR et al. Ginger root - a new antiemetic; the effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia. 1990; 45:669-71.
315. Kraynack BJ, Bates MF, Gintautas J. Antiemetic efficacy of ranitidine, metoclopramide and gastric suctioning in outpatient laparoscopy. Anesth Analg. 1990; 70:S218. Abstract.
316. Raphael JH, Norton AC. Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. Br J Anaesth. 1993; 71:845-8.
317. DeVries PM. A double-blind cross-over clinical evaluation of metoclopramide and a combination of haloperidol and isopropamide iodide in gastroenterology. Arzneimittelforschung. 1969; 19:1766-7.
318. Tornetta FJ. Double-blind evaluation of haloperidol for antiemetic activity. Anesth Analg. 1972; 51:964-7.
319. Lind B, Breivik H. Metoclopramide and perphenazine in the prevention of postoperative nausea and vomiting. Br J Anaesth. 1970; 42:614-7.
320. McGarry JM. A double-blind comparison of the anti-emetic effect during labour of metoclopramide and perphenazine. Br J Anaesth. 1971; 43:613-5.
321. Shaklai M, Pinkhas J, De Vries A. Metoclopramide and cardiac arrhythmia. Br Med J. 1974; 1:385.
322. Park GR. Hypotension following metoclopramide administration during hypotensive anaesthesia for intracranial aneurysm. Br J Anaesth, 1978; 50:1268-9. Letter.
323. Pegg MS. Hypotension following metoclopramide injection. Anaesthesia. 1980; 35:615. Letter.
324. Withington DE. Dysrhythmias following intravenous metoclopramide. Intens Care Med. 1986; 12:378-9.
325. Bevacqua BK. Supraventricular tachycardia associated with postpartum metoclopramide administration. Anesthesiology. 1988; 68:124-5.
326. Friedman LS, Weinrauch LA, D'Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987; 147:1495-7.
327. Wetchler BV, Sung YF, Duncalf D. Ondansetron decreases emetic symptoms following outpatient laparoscopy. Anesthesiology. 1990; 73:A36. Abstract.
328. Bodner M, White PF. Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg. 1991; 73:250-4.
329. Larijani GE, Gratz I, Afshar M et al. Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. Anesth Analg. 1991; 73:246-9.
330. 3 receptor antagonist. Anesth Analg. 1991; 72:751-5.
331. Lessin JB, Azad SS, Rosenblum F et al. Does antiemetic prophylaxis with ondansetron prolong recovery time? Anesth Analg. 1991; 72:S162. Abstract.
332. Rosenblum F, Azad SS, Bartkowski R et al. Ondansetron: a new, effective anti-emetic prevents postoperative nausea and vomiting. Anesth Analg. 1991; 72:S230. Abstract.
333. Bouly A, Nathan N, Feiss P. Prevention of postoperative nausea and vomiting by ondansetron. Ann Fr Anesth Reanim. 1992; 11:496-501.
334. Dershwitz M, Rosow CE, Di Biase PM et al. Ondansetron is effective in decreasing postoperative nausea and vomiting. Clin Pharmacol Ther. 1992; 52:96-101.
335. Helmers JHJH. Oral ondansetron in the prevention of post-operative nausea and vomiting. Eur J Anaesthesiol. 1992; 9(suppl 6):49-54.
336. Kenny GN, OatesJD, Leeser J et al. Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. Br J Anaesth, 1992; 68:466-70.
337. Kovac A, McKenzie R, O'Connor T et al. Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. Eur J Anaesth. 1992; 9(suppl 6):37-47.
338. Dupeyron JP, Conseiller C, Levarlet M et al. The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anesthesia. Anaesthesia. 1993; 48:214-8.
339. Helmers JHJH, Briggs L, Abrahamsson J et al. A single iv dose of ondansetron 8mg prior to induction of anaesthesea reduces postoperative nausea and vomiting in gynaecological patients. Can J Anaesth. 1993;40:1155-61.
340. Khalil SN, Kataria B, Pearson K et al. Ondansetron prevents postoperative nausea and vomiting in women outpatients. Anesth Analg. 1994; 79:845-51.
341. Sung YF, Wetchler BV, Duncalf D et al. A double-blind placebo-controlled pilot study examining the effectiveness of intravenous ondansetron in the prevention of postoperative nausea and emesis. J Clin Anesth. 1993; 5:22-9.
342. McKenzie R, Kovac A, O'Connor T et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology. 1993; 78:21-8.
343. McKenzie R, Sharifi-Azad S, Dershwitz M et al. A randomized, double-blind pilot study examining the use of intravenous ondansetron in the prevention of postoperative nausea and vomiting in female inpatients. J Clin Anesth. 1993; 5:30-6.
344. 3 antagonist ondansetron. Anesthesiology. 1993; 78:15-20.
345. Claybon L. Single dose intravenous ondansetron for the 24-hour treatment of postoperative nausea and vomiting. Anaesthesia. 1994; 49(suppl):24-9.
346. Can TJ, Collis R, Hetreed M. Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. Br J Anaesth. 1994; 72:544-7.
347. Malins AF, Field JM, Nesling PM et al. Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. Br J Anaesth. 1994; 72:231-3.
348. Pearman MH. Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia. 1994; 49(suppl):11-5.
349. Rodrigo MR, Campbell RC, Chow J et al. Ondansetron for prevention of postoperative nausea and vomiting following minor oral surgery: a double-blind randomized study. Anaesth Intens Care. 1994; 22:576-9.
350. Rust M, Cohen LA. Single oral dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia. 1994; 49(suppl):16-23.
351. Suen TK, Gin TA, Chen PP et al. Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. Anaesth Intern Care. 1994; 22:142-6.
352. Paxton LD, McKay AC, Mirakhur RK. Prevention of nausea and vomiting after day case gynaecological laparoscopy: a comparison of ondansetron, droperidol, metoclopramide, and placebo. Anaesthesia. 1995; 50:403-6.
353. Polati E, Finco G, Bartoloni A et al. Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients. Minerva Anestesiol. 1995; 61:373-9.
354. Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Br J Anaesth. 1996; 76:316-8.
355. Koivuranta MK, Laara E, Ryhanen PT. Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. Anaesthesia. 1996; 51:52-5.
356. Rose JB, Martin TM, Corddry DH et al. Ondansetron reduces the incidence and severity of poststrabismus repair vomiting in children. Anesth Analg. 1994; 79:486-9.
357. Watcha MF, Bras PJ, Ceislak GD et al. The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients undergoing ambulatory surgery. Anesthesiology. 1995; 82:47-52.
358. Litman RS, Wu CL, Catanzaro FA. Ondansetron decreases emesis after tonsillectomy in children. Anesth Analg. 1994; 78:478-81.
359. Splinter WM, Baxter MR, Gould HM et al. Oral ondansetron decreases vomiting after tonsillectomy in children. Can J Anaesth. 1995; 42:277-80.
360. Khalil S, Rodarte A, Weldon BC et al. Intravenous on-dansetron in established postoperative emesis in children. S3A-381 Study Group. Anesthesiology. 1996; 85:270-6.
361. Ulusoy HO, Akturk G, Luleci N et al. Prophylactic administration of ondansetron in emergency intraabdominal operations. Middle East J Anesthesiol. 1996; 13:513-26.
362. Kovac AL, Pearman MH, Khali SN et al. Ondansetron prevents postoperative emesis in male outpatients. J Clin Anesth. 1996; 8:644-51.
363. Rose JB, Brenn BR, Corddry DH et al. Preoperative oral ondansetron for pediatric tonsillectomy. Anesth Analg. 1996; 82:558-62.
364. Fujji Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth. 1994; 41:794-7.
365. Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth. 1994; 41:291-4.
366. Fujii Y, Tanaka H, Toyooka H. Granisetron reduces vomiting after strabismus surgery and tonsillectomy in children. Can J Anaesth. 1996; 43:35-8.
367. Fujii Y, Toyooka H, Tanaka H. Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness. Can J Anaesth. 1996; 43:110-4.
368. Fujii Y, Toyooka H. Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery. Can J Anaesth. 1996; 43:1095-9.
369. Cieslak GD, Watcha MF, Phillips MB et al. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric emesis. Anesthesiology. 1996; 85:1076-85.
370. Naguib M, el Bakry AK, Khoshim MH et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth. 1996; 43:226-31.
371. Wilson AJ, Diemunsch P, Lindeque BG et al. Single-dose IV granisetron in the prevention of postoperative nausea and vomiting. Br J Anaesth. 1996; 76:515-8.
372. Fujii Y, Tanaka H, Toyooka H. Granisetron-dexamethasone combination reduces postoperative nausea and vomiting. Can J Anaesth. 1995; 42:387-90.
373. Mikawa K, Takao Y, Nishina K et al. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Anesth Analg. 1995; 80:970-4.
374. Graczyk SG, McKenzie R, Kallar S et al. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Anesth Analg. 1997; 84:325-30.
375. Korttila K, Maillet M, Diemunsch P et al. IV dolasetron mesylate (DM) vs IV ondansetron (OND) for prevention of post operative nausea and vomiting (PONV). Anesthesiology. 1996; 86(3A suppl):A35. Abstract.
376. Diemunsch P, Leeser J, Feiss P et al. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting. Can J Anaesth. 1997; 44:173-81.
377. Diemunsch P, D'Hollander A, Paxton L et al. Intravenous dolasetron mesylate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery. J Clin Anesth. 1997; 9:365-73.
378. Kovac A, Melson T, Graczyk S et al. Treatment of postoperative nausea and vomiting with single doses of IV dolasetron: a multicenter trial. Anesthesiology. 1995; 83(3A suppl):A6. Abstract.
379. Watkins WD, Kovac A, Hickok C et al. Evaluation of optimally effective IV dose of dolasetron mesylate (DM) for treating established post operative nausea and vomiting (PONV). Anesthesiology. 1996; 85(3A suppl):A17. Abstract.
380. Diemunsch P, Leeser J, Helmers JH et al. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting (PONV). Anesthesiology. 1996; 85(3A suppl):A3. Abstract.
381. Warriner CB, Knox D, Belo S et al. Prophylactic oral dolasetron mesylate reduces postoperative nausea and vomiting following abdominal hysterectomy. Anesthesiology. 1995; 83(3A):A312. Abstract.
382. Pan PH, Moore CH. Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. Anesth Analg. 1996; 83:982-6.
383. Alon E, Biro P, Lenzlinger PM et al. Ondansetron as prophylaxis for postoperative nausea and vomiting. A prospective randomized double-blind comparative trial with droperidol. Anaesthestist. 1994; 43:500-3.
384. Tang J, Watcha MF, White PF. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Anesth Analg. 1996; 83:304-13.
385. Watcha MF, Smith I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth. 1994; 6:370-7.
386. Litman RS, Wu CL, Lee A et al. Prevention of emesis after strabismus repair in children: a prospective, double-blinded, randomized comparison of dioperidol versus ondansetron. J Clin Anesth. 1995; 7:58-62.
387. Fujii Y, Tanaka H, Toyooka H. Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth. 1997; 44:396-400.
388. Howat DDC. Anti-emetic drugs in anaesthesia: a double blind trial of two phenothiazine derivatives. Anaesthesia. 1960; 15:289-97.
389. Cramb R, Fargas-Babjak A, Hirano G. Intraoperative prochlorperazine for prevention of postoperative nausea and vomiting. Can J Anaesth. 1989; 36:565-7.
390. Patterson KW, Armstrong C, Timon D et al. The value of buccal prochlorperazine in the prevention of post-operative nausea and vomiting. J Ir Coll Physic Surg. 1991; 20:200-2.
391. Moore DC, Bridenbaugh LD, Piccioni VF et al. Control of postoperative vomiting with marezine: a double-blind study. Anesthesiology. 1956; 17:690-5.
392. Tillman WW, Wise GF, Crawford OB. Evaluation of Marezine and Bonamine in lowering the incidence of postoperative nausea and vomiting. Anesthesiology. 1956; 17:112-5.
393. Bonica JJ, Crepps W, Monk B et al. Postanesthetic nausea, retching and vomiting: evaluation of cyclizine (Marezine) suppositories for treatment. Anesthesiology. 1958; 19:532-40.
394. Bellville JW, Brass ID, Howland WS. The antiemetic efficacy of cyclizine (Marezine) and triflupromazine (Vesprin). Anesthesiology. 1959; 20:761-6.
395. Dundee JW, Assaf RAE, Loan WB et al. A comparison of the efficacy of cyclizine and perphenazine in reducing the emetic effects of morphine and pethidine. Br J Clin Pharm. 1975; 2:81-5.
396. Larrauri RM. Benzquinamide parenteral for the treatment of post-operative nausea and vomiting. Curr Ther Res Clin Exp. 1969; 11:118-20.
397. Klein RL, Graves CL, Kim Y et al. Inhibition of apomorphine-induced vomiting by benzquinamide. Clin Pharmacol Ther. 1970; 11:530-7.
398. Finn H, Urban BJ, Thomas JS et al. Antiemetic efficacy of benzquinamide. N Y State J Med. 1971; 71:651-3.
399. Lutz H, Immich H. Antiemetic effect of benzquinamide in post-operative vomiting. Curr Ther Res Clin Exp. 1972; 14: 178-84.
400. Taylor E, Monk TG, White PF. Use of dronabinol for preanesthetic medication. Anesthesiology. 1990; 73:A386. Abstract.
401. Purkis IE. The action of thiethylperazine (Torecan), a new anti-emetic, compared with perphenazine (Trilafon), trimethabenzamide (Tigan) and a placebo in the suppression of postanaesthetic nausea and vomiting. Can Anaesth Soc J. 1965; 12:595-607.
402. Dobkin AB, Evers W, Israel JS, Double-blind evaluation of metoclopramide (MK 745, Sinemet), trimethobenzamide (Tigan) and a placebo as postanaesthetic anti-emetics following methoxyflurane anaesthesia. Can Anaesth Soc J. 1968; 15:80-91.
403. Knapp MR, Beecher HK. Postanesthetic nausea, vomiting and retching: evaluation of the antiemetic drugs dimenhydrinate (Dramamine), chlorpromazine, and pentobarbital sodium. JAMA. 1956; 160:376-85.
404. Battersby C. A clinical trial of thiethylperazine (Torecan) suppositories in postoperative nausea and vomiting. Med J Aust. 1965; 2:450-2.
405. Khanna SK, Anand SS, Saini VK. Control of postoperative vomiting by thiethylperazine. J Indian Med Assoc. 1965; 45:5958.
406. Albert SN, Coakley CS. The use of chlorpromazine to control postanaesthetic vomiting. Curr Res Anesth Analg. 1954; 33:285-8.
407. Boulton TB. Oral chlorpromazine hydrochloride: a clinical trial in thoracic surgery. Anaesthesia. 1955; 10:233-46.
408. Caplin D, Smith C. A comparison of the anti-emetic effects of dimenhydrinate, promethazine hydrochloride and chlorpromazine following anaesthesia. Can Anaesth Soc J. 1955; 2: 191-7.
409. Dyrberg V, Johansen SH. Pre-anesthetic medication with chlorpromazine: a comparison with morphine. Acta Anaesthesiol Scand. 1958; 2:133-47.
410. Kvisselgaard N. Chlorptomazine and chlorcyclizine I in the prevention of postoperative nausea and vomiting. Acta Anaesthesiol Scand. 1958; 2:153-62.
411. Barton MD, Libonati M, Cohen PJ. The use of haloperidol for treatment of postoperative nausea and vomiting - a double-blind placebo-controlled trial. Anesthesiology. 1975; 42:508-12.
412. Rothenberg DM, Parnass SM, Litwack K et al. Efficacy of ephedrine in the prevention of postoperative nausea and vomiting. Anesth Analg. 1991; 72:58-61.
413. Snow JC. Hydroxyzine for postoperative nausea and vomiting following ophthalmologic surgery. Anesth Analg. 1965; 44:487-91.
414. Moore DC, Bridenbaugh LD, Van Ackeren EG et al. Control of postoperative vomiting with perphenazine (Trilafon): a double-blind study. Anesthesiology. 1958; 19:72-4.
415. Scurr CF, Robbie DS. Trials of perphenazine in the prevention of post-operative vomiting. Br Med J. 1958; 1:922-3.
416. Braly BB, Moore DC. The use of intramuscular perphenazine control for postoperative vomiting following strabismus surgery in children. Anesthesiology. 1990; 77:245-8.
417. Splinter WM, Roberts DJ. Perphenazine decreases vomiting by children after tonsillectomy. Can J Anaesth. 1997; 44:1308-10.
418. Splinter W, Noel LP, Roberts D et al. Antiemetic prophylaxis for strabismus surgery. Can J Ophthalmol. 1994; 29:224-6.
419. Transderm Scop package insert. East Hanover, NJ: Novartis; 1996 Aug.
420. Rung GW, Claybon L, Hord A et al. Intravenous on-dansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group. Anesth Analg. 1997; 84:832-8.
421. DuPen S, Scuderi P, Wetchler B et al. Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. Eur J Anaesthesiol. 1992; 9(suppl 6):55-62.
422. Diemunsch P, Leeser J, Feiss P et al. Dolasetron mesylate treats established nausea and vomiting after general surgery. Anesthesiology. 1995; 83(3A):A1109. Abstract.
423. Goldberg ME, Vekeman D, Torjman M. Intravenous dolasetron (D) versus placebo (P) for the treatment of post operative nausea and vomiting (PONV). Anesth Analg. 1996; 82(2 suppl):S133. Abstract.